Logo

 

Recent News

Events

Publications

 

Recent News

news

 

Signal Genetics Announces Launch of New Physician Web Portal and Genetic Test Results Analysis Tool — ResultsPX™ Provides Immediate, Secure Access to Key Information to Improve Cancer Treatment Decisions

New York, NY, March 1, 2012 –Signal Genetics, a privately held cancer genetics testing company, today announced the launch of its new physician portal and analysis tool, ResultsPX™.  The HIPAA compliant web portal will enhance physicians’ ability to administer and analyze the results of Signal Genetics’ predictive genomic tests, including MyPRS Plus™ for multiple myeloma and Previstage™ GCC for colon cancer staging and recurrence. (download pdf)

 

Signal Genetics Announces Acquisition of ChipDX LLC and Expansion of Molecular Diagnostics Assets in Oncology

New York, NY, February 2, 2012 – Signal Genetics, a privately held predictive genetic testing company focused on oncology, today announced an agreement with New York based ChipDX LLC (“ChipDX”), under which Signal will acquire all of the assets of ChipDX, including patents for prognostic tests in lung, breast, and colon cancers. As part of the transaction, Signal will acquire BreastGeneDX®, ColonGeneDX®, and LungGeneDX®, all diagnostic and prognostic tests in development by ChipDX. Signal believes that these genetic tests represent novel products or improvements over other products currently on the market in these cancer types. Signal will also acquire ChipDX’s web-based interface, which will be used to enhance Signal’s physician web portal and allow for remote interpretation of test algorithms. Ryan VanLaar, Ph.D., CEO and Founder of ChipDX, will join Signal as the Head of BioInformatics. Financial details of the transaction were not disclosed. (download pdf)

 

Signal Genetics Announces Launch of Next Generation Genetic Multiple Myeloma Predictive Testing Product – MyPRS Plus™

SAN DIEGO, CA, December 9, 2011–Signal Genetics announced today, at the American Society of Hematology Annual Meeting, that the Company is launching its next generation Multiple Myeloma product, MyPRS Plus™, effective January 1, 2012. Signal Genetics is a privately held predictive genetic testing company focused on oncology.  In addition to providing the benefits of the earlier product, which  effectively stratifies Multiple Myeloma patients between those at high vs. low risk for relapse and overall survival, MyPRS Plus™ provides additional insights in to the genetic characteristics of each individual patient and identifies the molecular sub-group to which each patient belongs.  This classification is the most granular predictor of relapse and survival available for Myeloma patients. (download pdf)

 

NeoGenomics Inks Distribution Deal for Signal Genetics' Multiple Myeloma Gene Expression Test

New York, NY – May 26, 2011 (GenomeWeb News) – NeoGenomics Laboratories will offer Signal Genetics' new gene expression profile test for multiple myeloma to pathologists and hospital-based hematologists and oncologists nationwide under a deal announced today.

Under the terms of the agreement, Signal Genetics' Myeloma Prognostic Risk Signature test will be performed at its CLIA-certified laboratory in Little Rock, Ark., and results will be incorporated into NeoGenomics' test reports to be provided to its customers along with other ancillary diagnostic tests, Signal Genetics said. (download pdf)

 

Effective March 4, 2011, Medicare approved coverage for MyPRS™ for Medicare beneficiaries. 

Click here for details regarding the coverage policy.

 

Plethora of New Products to be Showcased at 2011 Molecular Medicine Tri-Conference

Needham, MA – February 7, 2011 – Cambridge Healthtech Institute announces 43 exhibitors to showcase new products at the 18th Molecular Medicine Tri-Conference, taking place February 23-25, at the Moscone Convention Center, San Francisco, CA.  The Molecular Medicine Tri-Conference is the predominant event on the west coast focused on integrating the entire spectrum of drug development. (download pdf)

 

Caris will offer Signal’s Myeloma Prognostic Risk Signature (MyPRS) gene expression profile test

New York, NY and Irving, Texas, January 10, 2011 Caris will offer Signal’s Myeloma Prognostic Risk Signature (MyPRS) gene expression profile test to community-based hematologists and medical oncologists in the U.S. MyPRS analyzes and applies an algorithm to a defined number of relevant genes to determine the gene expression profile associated with the patient’s condition. (download pdf)

 

Signal clinches maiden deal for gene profiling cancer test with Caris

By Tina Tan, Clinica, January 7, 2011 – Signal Genetics has enlisted Caris Life Sciences to sell its new gene expression profile test in the US. The test is used in patients with multiple myeloma, a cancer of the white blood cells. This is the first commercial deal for Signal's MyPRS (myeloma prognostic risk signature) test since it was launched last month at the annual meeting of the American Society of Hematology, held in Orlando, Florida. Previously, the product was available only on a research basis, said Greg Richard, Signal's executive vice-president of commercial operations. (download pdf)

 

Signal Genetics and Caris Life Sciences Announce Commercialization Partnership for New Myeloma Gene Expression Test

New York, NY and Irving, Texas, January 5, 2011 – Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics’ new gene expression profile test for Multiple Myeloma (MyPRS™) to community-based hematologists/medical oncologists nationwide. (download pdf)


Signal Genetics Announces Launch of Revolutionary Molecular Test for Multiple Myeloma Patients

New York, NY, December 1, 2010 – Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the launch of their revolutionary molecular test for individuals diagnosed with multiple myeloma, MyPRS™. (download pdf)


Signal Genetics Announces Establishment of Scientific Advisory Board

New York, NY, October 26, 2010 – Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the formation of their Scientific Advisory Board. (download pdf)

Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics

New York, NY, September 22, 2010 – Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the company will work with Array BioPharma to help push forward both companies’ goals of markers for patient selection helping bring personalized medicine and companion diagnostics to patients with multiple myeloma, a cancer of the bone marrow and antibody producing cells. (download pdf)


Signal Genetics Announces Licensing Agreement of Novel Microarray Diagnostic for the Predictive Determination of Multiple Myeloma Staging & Prognosis with University of Arkansas Medical Sciences

New York, NY, September 7, 2010 – Signal Genetics, a privately held predictive genetic testing company directed toward cancer patients, today announced that the company has acquired an exclusive license to technologies developed at the University of Arkansas Medical Sciences. (download pdf)